Special Issue

The Role of Long Non-coding RNA in Cancer

Message from the Guest Editor

The role of lncRNAs is still unclear and currently under investigation in cancer progression, dormancy, and metastasis. LncRNAs are a class of transcripts with diverse and largely uncharacterized biological functions involved in various biological processes and have been proposed to be key players in diseases including cancers. Through crosstalk with chromatin, DNA, RNA species and proteins, lncRNAs play an important role in chromatin remodeling, as well as transcriptional and post-transcriptional regulation. The lncRNAs mediated genetic or epigenetic alterations in disseminated tumor cells regulate metastatic niches which play a significant role to define the fate of dormant tumor cells in reactivation. The rate-limiting step of the metastatic process can be influenced by various immune cells in a tumor microenvironment (TME). Despite all these findings, the role of tumor intrinsic LncRNAs in the regulation of metastatic reactivation and immune evasion remains unclear. Understanding the mechanisms of lncRNAs during cancer dormancy, metastasis and tumor immune microenvironment would be highly valuable to identify novel targets to combat cancer metastasis and relapse.

Guest Editor

Dr. Dhiraj Kumar

Department of Genetics and Development, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA

Deadline for manuscript submissions

closed (31 August 2023)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/165716

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).